Embed Size (px)
Citation preview
Supplementary Table 1: Main Characteristics of Included Studies
Authors Drug(s) Drug rangeor
mean dosage (mg)
Concomitant anxiolytics
Study duration (weeks)
Time considered
in our study as endpoint
Number of
subjects (ITT)
% female
Mean Age
Comorbidities Patients having
INSOMNIA as side effect
Patients having SOMNOLENCE
as side effect
Sponsor
(Abbasi et al. 2012)(65)
Sertraline + Placebo
200 No 6 T6 20 30 34.2±6.9 No 1 - No
(Abolfazli et al. 2011)
(
66)_ENREF_2
Fluoxetine + Placebo
40 No 6 T6 22 50 33.3±6.1 No 5 - No
(Aguglia et al. 1993)(67)
Fluoxetine
Sertraline
28
72
Yes 8 T8 48
40
87.5
97.5
58.9±17.3
57.5±15.5
No 2
1
1
4
No
(Akhondzadeh et al. 2003)(68)
Fluoxetine 60 No 6 T6 24 62.5 36.2±8.1 No 4 7 No
(Akhondzadeh et al. 2009)(69)
Fluoxetine + Placebo
40 No 6 T6 20 60 34.2±4.96 No 4 - No
(Akkaya et al. 2006)(70)
Reboxetine
Venlafaxine
8
150
No 10 T10 50
43
74
81.4
40.4±10.7
42.0±11.0
No -
-
22
1
No
(Alvarez et al. 2012)(71)
Venlafaxine
Placebo
225 Yes 6 T6 113
105
54.9
65.7
45.0±10.3
42.0±10.9
No 14
5
-
-
Yes
(Amini et al. 2005)(72)
Fluoxetine
Mirtazapine
20
30
Yes 6 T6 15
16
60
68.8
37.7±11.3
35.0±10.6
No -
-
2
6
No
(Andreoli et al. 2002)(73)
Reboxetine 8-10 Yes 8 T8 126 67 40.0±.12.0 No 23 - No
Fluoxetine 20-40 127 65 40.0±.11.5 15 -
(Ansseau et al. 1994)
(
74)_ENREF_11
Paroxetine 20-30 No 6 T6 56 46.4 43.7± 11.5 No - 5 Yes
(Appelhof et al. 2004)(75)
Paroxetine + Placebo
30 Yes 8 T8 45 64 46.2±11.2 No 19 21 No
(Baldwin et al. 2008)(76)
Milnacipran 100 No 12 T12 80 80 41.8±10.0 No 10 - Yes
(Baldwin et al. 2012)(77)
Duloxetine
Placebo
60 Yes 8 T8 155
148
67.7
69.6
45.3±12.0
43.4±12.5
No 13
6
-
-
Yes
(Behnke et al. 2003)(61)
Mirtazapine
Sertraline
38.3
92.7
Yes 8 T8 176
169
55.7
61.5
42 ± 11
41 ± 12
No 9
15
35
13
Yes
(Benkert et al. 2000)(78)
Mirtazapine
Paroxetine
32.7
22.9
Yes 6 T6 135
134
63
65
47.2± 11.1
47.3± 10.3
No -
-
15
10
Yes
(Benkert et al. 2006)(79)
Venlafaxine 225 No 6 T6 115 - - No 17 - Yes
(Benkert et al. 1996)(80)
Venlafaxine 225 Yes 6 T6 85 69.4 48.9± 11.7 No 8 - No
(Berk et al. 1997)(81)
Duloxetine 20 Yes 6 T6 80 77.5 38 No 17 7 No
(Berzewski et al. 1997)(82)
Reboxetine 8-20 Yes 6 T6 130 64.6 45.4± 12.0 No 10 4 No
(Bielski et al. 2004)(83)
Escitalopram 20 Yes 8 T8 97 69.4 37.3± 12.3 No - 9 Yes
Venlafaxine 225 98 47 37.5± 11.6 - 17
(Blier et al. 2010)(84)
Fluoxetine + Placebo
20 Yes 6 T6 28 - 43.8 ± 1.8 No 3 3 Yes
(Blier et al. 2009)(85)
Mirtazapine
Paroxetine
30-45
20-30
No 6+16 T6 21
19
23.8
52.6
46 ± 9
40 ± 12
No 5
8
11
5
Yes
(Bondareff et al. 2000)(86)
Sertraline 96 ± 41 Yes 12 T12 104 60.6 67.8 ± 6.0 No 21 5 Yes
(Bose et al. 2008)(87)
Escitalopram
Placebo
14 No 12 T12 130
134
59
60
68.1± 6.7
68.5±7.1
No 10
17
-
-
Yes
(Boyer et al. 2000)(88)
Sertraline 79.17 No 8 T8 140 61.4 39.87 No 10 - No
(Boyer et al. 2008)(89)
Desvenlafaxine
Desvenlafaxine
Placebo
50
100
No 8 T8 164
158
161
70
71
68
44±14
46±13
46±12
No 13
14
7
- Yes
(Brannan et al. 2005)(90)
Duloxetine
Placebo
60 Yes 7 T7 141
141
68.1
62.4
40.8±13.5
40.3±13.5
No 15
9
-
-
Yes
(Brecht et al. 2007)(91)
Duloxetine
Placebo
60 No 8 T8 162
165
75.9
71.5
48.1
52.3
No 6
3
-
-
Yes
(Bremner et al. 1995)(92)
Mirtazapine
Placebo
22 No 6 T6 50
50
60
70
39
37
No -
-
23
11
Yes
Brown (2005)(93)
Citalopram 20-60 No 12 T12 41 80.5 40.4± 10.8 No 9 - No
Placebo 41 80.5 42.9± 10.1 13 -
(Brown et al. 1995)(94)
Sertraline 117.7±58.5 No 8 T8 112 69.6 42.3± 12.8 No 27 11 Yes
(Burke et al. 2002)(95)
Citalopram
Escitalopram
Escitalopram
Placebo
40
10
20
Yes 8 T8 125
118
123
119
62
70
68
60
40.0±11.5
40.7±12.3
39.6±12.0
40.1±10.6
No 11
10
14
3
-
-
-
-
Yes
(Byerley et al. 1988)(96)
Fluoxetine
Placebo
20-80 Yes 6 T6 32
29
75
61
38.9±10.7
37.5±9.1
No 4
2
-
-
Yes
(Calabrese et al. 2003)(97)
Citalopram 24.6 No 6 T6 55 73 43 No 2 1 Yes
(Chouinard et al. 1999)
(
98)_ENREF_104
Paroxetine
Fluoxetine
25.5
27.5
Yes 12 T12 102
101
40.6± 10.7
41.2± 10.7
No No
(Claghorn et al. 1992)(99)
Paroxetine
Placebo
30 No 6 T6 168
179
50
54
40.6
42.8
Personality disorders
25
8
34
14
Yes
(Claghorn et al. 1995)(100)
Mirtazapine
Placebo
16.5 Yes 6 T6 42
40
52.4
45
39
40
No -
-
27
2
Yes
(Claghorn et al. 1996)(101)
Fluvoxamine
Placebo
92.7 ± 46.9 No 6 T6 50
50
64
64
39.0±10.9 No 3
5
19
4
No
(Clayton et al. 2006)(102)
Bupropion
Escitalopram
300-450
10-20
Yes 8 T8 276
281
58
57
37±12
36±11
No 39
28
8
22
Yes
Placebo 273 60 36±11 21 14
(Clerc et al. 1994)(103)
Venlafaxine
Fluoxetine
200
40
No 6 T6 33
34
69.7
67.6
49.0
53.6
No 0
1
-
-
Yes
(Clerc et al. 2001)(104)
Fluvoxamine
Milnacipran
200
100
Yes 6 T6 56
57
82.1
75.4
51.2± 12.6
48.7± 15.1
No 1
0
6
1
Yes
(Cohn et al. 1985)(105)
Fluoxetine
Placebo
20-80 No 6 T6 54
58
72.2
63.6
41
44
No 11
4
20
9
No
(Cohn et al. 1992)(106)
Paroxetine
Placebo
30.9 Yes 6 T6 40
40
60
42.5
42.3
41.3
No 8
5
9
7
No
(Coleman et al. 1999)(107)
Bupropion
Sertraline
Placebo
290
106
Yes 8 T8 119
115
121
56
54
59
38.1
38.3
38.5
No 24
20
8
-
-
-
Yes
(Coleman et al. 2001)(108)
Bupropion
Fluoxetine
Placebo
319
26
No 8 T8 150
154
152
63
66
61
36.6
37.1
36.7
No 21
15
10
4
17
6
Yes
(Cooper-Kazaz et al. 2007)
(109)
Sertraline + Placebo
85.5 ± 15.7 Yes 8 T8 50 58 41.0± 55.8 No 31 34 No
(Corrigan et al. 2000)(110)
Fluoxetine
Placebo
20 No 8 T8 33
34
-
-
42
42
No 6
1
3
2
No
(Costa e Silva 1998)(111)
Fluoxetine
Venlafaxine
20-40
75-150
Yes 8 T8 185
194
77.8
80.9
39.8± 10.3
40.5± 10.7
No 15
12
3
16
No
(Cunha et al. 2007)(112)
Venlafaxine
Placebo
75 No 6 T6 14
17
85.7
64.7
77.6 ±7.3
77.6 ±5.8
Mild or moderate dementia
0
2
1
1
No
(Cunningham et al. 1994)(113)
Venlafaxine
Placebo
156-160 Yes 6 T6 72
76
-
-
40.7
40.7
No -
-
31
9
Yes
(Cunningham et al. 1997)(114)
Venlafaxine XR
Venlafaxine IR
Placebo
115-125
124-140
Yes 12 T12 97
96
100
63.0
66.6
58.6
39.7± 11.0
42.8± 11.4
39.9± 10.1
No -
-
-
20
23
9
Yes
(Currier et al. 2003)(115)
Bupropion 265± 65 No 6 T6 20 30 41.0 ±7.0 No 4 - Yes
(Currier et al. 2004)(116)
Citalopram 31.3± 11.1 No 6 T6 17 29.4 42.9± 8.4 Dysthymia 3 - Yes
(Dam et al. 1998)(117)
Fluoxetine + Placebo
20 No 6 T6 17 - - No 2 0 Yes
(Serretti et al. 2005)(23)
Fluvoxamine - Yes 6 T6 61 73.4 55.7 Personality disorders
2 - No
(De Montigny et al. 1999)
(118)
Venlafaxine 260 No 8 T8 158 72.2 42.9± 9.2 Dysthymia 74 - Yes
(Debus et al. 1988)(119)
Fluoxetine 31.4 No 6 T6 18 61.1 35.4± 8.6 No 3 7 Yes
(DeMartinis et al. 2007)(120)
Desvenlafaxine
Desvenlafaxine
Desvenlafaxine
Placebo
100
200
400
No 8 T8 118
116
116
120
65
61
54
68
40.4±12.1
40.7±12.8
39.0±12.6
40.0±12.8
No 26
21
35
10
24
25
30
10
Yes
(Demir et al. Reboxetine 8-10 No 8 T8 24 83.3 - No 7 - No
2002)(121)
(Detke et al. 2002)(122)
Duloxetine
Placebo
60 Yes 9 T9 128
139
66
71
41±13
41±15
No 21
19
13
9
Yes
(Detke et al. 2004)(123)
Duloxetine
Duloxetine
Paroxetine
Placebo
80
120
20
Yes 8 T8 95
93
86
93
73.7
75.3
67.4
74.2
43.1 ±11.1
44.7±10.7
42.0±10.6
43.7±12.2
No 5
5
3
7
2
7
5
0
Yes
(Diaz-Martinez et al. 1998)
(124)
Fluoxetine
Venlafaxine
20-40
75-150
Yes 8 T8 75
70
78.6
64.3
37
37
No 18
22
15
15
Yes
(Dierick et al. 1996)(125)
Fluoxetine
Venlafaxine
20
75-112
Yes 8 T8 161
153
65.2
65.4
43.2± 13.0
43.7± 12.5
No 13
11
-
-
Yes
(Doogan et al. 1994)(126)
Sertraline
Placebo
50 Yes 6 T6 83
90
71.1
64.4
46.0
45.4
No -
-
2
0
No
(Dubè et al. 2010)(127)
Escitalopram
Placebo
15.2 Yes 8 T8 62
138
35.5
47.1
34.3±9.7
37.5±11.0
No 2
4
15
11
Yes
(Dunbar et al. 1991)(128)
Paroxetine
Placebo
10-50 No 6 T6 240
240
46.7
44.2
40.3
40.3
No -
-
27
11
Yes
(Dunner et al. 1992)(129)
Paroxetine 23.4 Yes 6 T6 136 73 68 No No
(Dunner et al. 2005)(130)
Duloxetine
Duloxetine
30-120
30-120
No 12 T12 67
70
56.7
62.9
42.3± 13.5
42.0± 12.6
No 12
12
8
9
Yes
(Eker et al. 2005)(131)
Reboxetine
Sertraline
14.4
50
No 10 T10 20
21
75
85.7
41.3 ± 9.1
40 ± 13.7
No -
-
4
1
No
(Elliott et al. 2000)(132)
Mirtazapine 46.9 ± 9.6 No 12 T12 12 8.3 36.9 ± 8.6 Dysthymia - 2 Yes
EMA Duloxetine study 2008
Duloxetine 60-120 Yes 6 T6 514 69.6 47.6± 13.3 No 27 16 Yes
EMA Sertraline study 1994
(Protocol N. 86CE21-0247)
Sertraline
Placebo
119.8 Yes 10 T10 43
42
67.4
52.4
70.4
78.5
No 4
7
11
6
Yes
EMA Sertraline study 1994
(Protocol N. 050-104)
Sertraline
Placebo
145 Yes 8 T8 149
150
-
-
-
-
No 26
16
29
18
Yes
EMA Sertraline study 1991
(Protocol N. 86CE21-0238)
Sertraline
Sertraline
Sertraline
Sertraline
Placebo
50
100
200
400
Yes 8 T8 40
39
43
37
40
70
79.5
62.8
67.6
70
37.5
38.6
37.3
37.3
37.3
No 12
12
20
12
9
5
5
7
5
5
Yes
EMA Venlafaxine study 1990
(Protocol N. 600-A-313-US)
Venlafaxine
Venlafaxine
Venlafaxine
Placebo
22
52.4
139.5
Yes 6+52 T6 79
76
79
78
69.6
69.7
60.8
69.2
38.9
38.0
38.8
38.2
No Yes
EMA Venlafaxine study 1990
Venlafaxine
Placebo
185.1 Yes 6+52 T6 70
79
70
68.3
40
39
No 7
3
31
9
Yes
EMA Venlafaxine study 1990
(Protocol N. 600A-302-US)
Venlafaxine
Placebo
160 Yes 6+52 T6 65
75
60
66.7
42.3
41.3
No 13
6
28
11
Yes
EMA Venlafaxine study 1998
(Protocol N.. 0600A1-372
US)
Fluoxetine
Venlafaxine
Placebo
20-80
75-375
Yes 6 T6 152
155
152
65.8
63.9
59.9
38.0± 9.9
40.0± 9.5
39.0± 10.6
No 39
51
15
18
27
16
Yes
EMA Venlafaxine study 1995
(Protocol N. 0600B-367-
EU)
Venlafaxine
Venlafaxine
Paroxetine
Placebo
74.8
148.2
20
Yes 8 T8 83
78
80
82
69.8
64.1
55
68.2
44.9±12.9
44.3±10.6
48.2±12.5
44.7±11.6
No 2
3
3
2
6
7
11
2
Yes
EMA Venlafaxine study 1996
(Protocol N. 0600B-209-US)
Venlafaxine
Placebo
176.6 Yes 8 T8 91
100
63.7
59
40
42
No 33
15
26
11
Yes
(Fabre et al. 1996)(133)
Fluvoxamine
Placebo
50-117 No 6 T6 46
44
76.1
68.2
-
-
No 11
2
19
2
Yes
(Fabre et al. 1992)(134)
Paroxetine
Placebo
28.7 Yes 6 T6 38
36
55.3
63.8
35.6
35.9
No -
-
10
6
No
(Fava et al. 1998)(135)
Fluoxetine 20-80 Yes 12 T12 54 - 41.3± 12.6 No 11 - Yes
Paroxetine
Placebo
20-50 55
19
-
-
41.3± 12.6
41.3± 12.6
16
2
-
-
(Fava et al. 2001)(136)
Mirtazapine 24.3-27.5 No 8 T8 50 60 43.8± 10.0 No 3 25 Yes
(Fava et al. 2005)(137)
Fluoxetine
Placebo
20 No 12 T12 47
43
53
65
36.7 ± 9.6
37.8± 12.0
No 5
6
6
3
Yes
(Fava et al. 2006)(138)
Fluoxetine + Placebo
Fluoxetine + Eszopiclone
20-40
20-40
No 8 T8 274
269
66.4
66.9
40.4± 11.3
41.6± 10.7
No -
-
20
23
No
(Fava et al. 2011)(139)
Escitalopram +Placebo
Escitalopram + Zolpidem
10
10
Yes 8+16 T8 190
192
63.7
63.2
43.0± 11.2
42.9± 12.0
No -
-
16
17
Yes
FDA Bupropion
study
Bupropion
Bupropion
Placebo
300
400
Yes 8 T8 376
114
385
-
-
-
-
-
-
No 41
18
23
7
3
8
Yes
FDA Citalopram
study
Citalopram
Placebo
10-80 Yes 8 T8 1063
446
-
-
-
-
No 159
6
186
45
Yes
FDA Desvenlafaxine
study I (Application
number 21-992)
Desvenlafaxine
Desvenlafaxine
Desvenlafaxine
Venlafaxine
100
200
400
75-225
Yes 8 T8 118
307
317
244
-
-
-
-
-
-
-
-
No 26
55
60
29
24
49
51
34
Yes
Placebo 803 - - 80 48
FDA Desvenlafaxine
study II (Reference ID:
3270749)
Desvenlafaxine
Desvenlafaxine
Desvenlafaxine
Desvenlafaxine
Placebo
50
100
200
400
Yes 8 T8 317
424
307
317
636
-
-
-
-
-
-
-
-
-
-
No 28
51
43
47
38
13
38
37
38
25
Yes
FDA Deuloxetine
study (Application
number 21-427)
Duloxetine
Placebo
20-40 Yes 8 T8 1139
777
-
-
-
-
No 125
47
80
23
Yes
FDA Escitalopram
study I (Application
number 21-323)
Escitalopram
Placebo
10-20 Yes 8 T8 715
527
-
-
-
-
No 64
24
23
12
Yes
FDA Escitalopram study I table 2 (Application
number 21-323)
Escitalopram
Escitalopram
Placebo
10
20
Yes 8 T8 310
125
311
-
-
-
-
-
-
No 22
17
12
12
11
3
Yes
FDA Escitalopram
study II
Citalopram
Escitalopram
Escitalopram
Placebo
20
10
20
Yes 8 T8 125
124
128
127
62.4
70.6
67.2
59.0
40 ± 11.5
40.6±12.3
39.6± 12.1
40.3± 10.6
No 14
12
17
4
-
-
-
-
Yes
FDA Fluvoxamine
Fluvoxamine 20-80 Yes 8 T8 1728 - - No 276 225 Yes
study Placebo 975 - - 88 58
FDA Mirtazapine study (ID: 3210056)
Mirtazapine
Placebo
21-32 Yes 8 T8 453
361
-
-
-
-
No -
-
245
65
Yes
FDA Paroxetine
study I (Reference ID:
3231319)
Paroxetine
Placebo
20-50 Yes 8 T8 421
421
-
-
-
-
No 55
25
97
38
Yes
FDA Paroxetine
study II
Paroxetine
Paroxetine
Paroxetine
Paroxetine
Placebo
10
20
30
40
Yes 8 T8 102
104
101
102
51
-
-
-
-
-
-
-
-
-
-
No -
-
-
-
-
13
19
21
22
4
Yes
FDA Paroxetine study III
Paroxetine
Placebo
25-62.5 Yes 8 T8 212
211
63.2
63.0
40.7
39.8
No 36
19
47
17
Yes
FDA Paroxetine study IV
Paroxetine
Placebo
12.5-50 Yes 12 T12 104
109
48.1
63.3
70.4±5.9
69.4±5.4
No 10
9
22
13
Yes
FDA Sertraline study (ID: 3254400)
Sertraline
Placebo
50-200 Yes 8 T8 861
853
-
-
-
-
No 138
77
112
51
Yes
FDA Venlafaxine
study I
Venlafaxine
Placebo
75-375 Yes 8 T8 1033
609
-
-
-
-
No 186
61
238
55
Yes
FDA Venlafaxine
Venlafaxine 75-375 Yes 8 T8 357 - - No 61 31 Yes
study II Placebo 285 - - 31 23
(Feiger et al. 1996)(140)
Sertraline 148 Yes 6 T6 82 48 43.0 ± 1.1 No 19 17 Yes
(Feighner et al. 1991)(141)
Bupropion
Fluoxetine
345± 60
26± 6
No 6 T6 60
60
63.3
63.3
40.9
42.9
No 10
7
4
5
Yes
(Feighner et al. 1999)(142)
Citalopram
Citalopram
Citalopram
Citalopram
Placebo
10
20
40
60
No 6 T6 131
130
131
129
129
63
66
60
53
55
38
39
39
38
38
No 17
20
28
31
14
12
17
29
25
5
Yes
(Feighner et al. (I) 1989)(143)
Fluoxetine
Placebo
80 No 6 T6 61
59
69
79
45.0±2.0
39.7±1.9
No -
-
5
2
No
(Feighner et al. (II) 1989)(144)
Fluvoxamine
Placebo
145 No 6 T6 31
19
77
89
41
41
No 4
3
9
1
No
(Ferreri et al. 2001)(145)
Fluoxetine 20 Yes 6 T6 38 71.1 45± 12 No - 0 Yes
(Finkel et al. 1999)(146)
Sertraline 102± 44 Yes 12 T12 38 67 74 ± 4.4 No 5 - No
(Flores et al. 2004)(147)
Mirtazapine 35.1 No 8 T8 142 - 18-70 No - 18 Yes
(Forlenza et al. 2001)(148)
Sertraline 50 Yes 8 T8 27 77.8 68.8 No 16 2 Yes
(Fornaro et al. 2011)(149)
Duloxetine 60 Yes 12+12 T12 40 60 47 ± 10.7 No 29 4 No
(Fortner et al. 1999)(150)
Bupropion 222± 18 No 8 T8 18 61.1 69.9 No 2 - Yes
(Garlow et al. 2012)(151)
Sertraline + Placebo
141.6±52.2 No 12 T12 77 68 41.4 ±11.5 No 21 - No
(Gaynor et al. (I) 2011)(152)
Duloxetine
Placebo
60 Yes 8 T8 262
266
68.7
69.2
46.2±13
45.7±13
No 24
8
-
-
Yes
(Gaynor et al. (II) 2011)(153)
Duloxetine
Placebo
60 No 8 T8 261
266
70.1
66.9
45.2 ±12.5
44.2 ±12.4
No 14
7
22
9
Yes
(Geretsegger et al. 1995)(154)
Paroxetine 20-30 Yes 6 T6 44 - 71.0± 5.9 No 3 - Yes
(Golden et al. 2002)(155)
Paroxetine CR
Paroxetine IR
Placebo
48.2
38.2
Yes 12 T12 212
217
211
63.2
69.1
63.0
40.7± 10.8
39.9± 11.4
39.7± 10.8
No -
-
-
49
47
17
Yes
(Goldstein et al. 2002)(156)
Duloxetine
Fluoxetine
Placebo
40-120
20
No 8 T8 70
33
70
62.9
57.6
68.6
42.3± 10.8
39.7±10.5
41.4±13.3
No 14
3
5
13
7
7
Yes
(Goldstein et al. 2004)(157)
Duloxetine
Duloxetine
Paroxetine
Placebo
40
80
20
No 8 T8 86
91
87
89
56
62
64
64
41±10
41±12
40±13
40±11
No 15
18
7
5
15
10
7
2
Yes
GSK Bupropion
study I
Bupropion 300 Yes 8 T8 816 - - No 131 - Yes
GSK Bupropion 150-450 Yes 8 T8 801 - - No 64 16 Yes
Bupropion study II
Escitalopram
Venlafaxine
Placebo
10-20
75-150
281
385
796
-
-
-
-
-
-
22
19
32
22
15
32
GSK Paroxetine study 1993
Paroxetine 30 Yes 8 T8 172 76.7 47.8 No 23 - Yes
(Guelfi et al. 1998)(158)
Fluoxetine
Milnacipran
Milnacipran
20
100
200
Yes 12 T12 100
93
96
75
60
66
5.8± 12.8
45.6±12.4
45.2± 12.5
No 10
4
4
-
-
-
Yes
(Guelfi et al. 2001)(159)
Mirtazapine
Venlafaxine
49.5 ± 8.3
255.0±59.8
Yes 8 T8 78
79
62.8
68.4
45.9±10.4
44.5± 10.8
No -
-
6
4
Yes
(Hale et al. 2010)(160)
Agomelatine
Fluoxetine
25-50
20-40
No 8 T8 250
263
77
78.3
41.8± 11.2
42.7±11.9
No -
-
15
9
Yes
(Halikas et al. 1995)(161)
Mirtazapine
Placebo
20.1 No 6 T6 49
49
42.9
59.2
63
62
No -
-
26
11
Yes
(Hewett et al. (I) 2010)(162)
Bupropion XR
Venlafaxine XR
Placebo
180
85
No 8 T8 203
198
187
63
68
67
45.6± 11.8
44.1±11.5
44.5±10.8
No 15
13
8
3
9
9
Yes
(Hewett et al. (II) 2010)(163)
Bupropion XR
Placebo
179 No 10 T10 211
207
74
70
70.9±5.6
71.3±5.9
No 13
8
-
-
Yes
(Higuchi et al. 2011)(164)
Paroxetine CR 25-50 No 8 T8 161 53 36.4± 11.5 No - 16 Yes
Paroxetine IR
Placebo
20-40 83
172
58
55
35.5± 10.4
36.8± 10.1
-
-
7
3
(Hong et al. 2003)(165)
Fluoxetine
Mirtazapine
30.7
34.1
Yes 6 T6 66
66
63.6
62.1
47.1± 15.5
47.2± 14.7
No -
-
3
8
Yes
(Høyberg et al.
1996) (166)
Mirtazapine 37.3 Yes 6 T6 56 78.6 70.5 No - 3 Yes
(Hsu et al. 2011)(167)
Citalopram
Sertraline
22.9 ± 8.5
57.1± 17.9
Yes 6 T6 21
21
52.4
66.7
43.4± 11.4
38.0± 13.8
No 1
3
1
3
No
(Hudson et al. 2007)
(
168)_ENREF_120
Duloxetine 30-60 Yes 12+26 T12 533 71.9 43.4± 12.7 Dysthymia 56 72 Yes
(Isaac et al. 2003)(169)
Milnacipran + Placebo
100 No 6 T6 39 51.3 32.3± 10.0 No 1 - No
(Jazayeri et al. 2008)(170)
Fluoxetine + Placebo
20 No 8 T8 16 75 35.1± 9.4 Dysthymia 1 2 No
(Jefferson et al. 2006)(171)
Bupropion
Placebo
300-450 Yes 8 T8 135
139
66
69
40.0
39.8
No 10
2
-
-
Yes
(Kamijima et al. 2006)(172)
Sertraline 85.0± 24.2 No 8+16 T8 361 60.4 40.4± 10.8 No - 64 Yes
(Kanemoto et al. 2004)(173)
Milnacipran 75-150 Yes 8 T8 66 56.1 56.8± 14.1 No - 1 No
(Kang et al. 2009)(174)
Mirtazapine
Venlafaxine
27.6 ± 8.6
141.4±62.4
No 8 T8 73
53
76.7
77.4
46.5± 12.6
47.2± 12.0
No 1
0
7
3
Yes
(Kaplan et al. 2002)(175)
Venlafaxine 142 No 6 or 8 T6 or T8 69 74.0 38.6 No 6 - Yes
(Kasper et al. 2005)(176)
Escitalopram
Fluoxetine
Placebo
10
20
Yes 8 T8 170
164
180
75
77
76
75±7
75±7
75±7
No 4
3
4
4
0
1
Yes
(Kasper et al. 2012)(177)
Escitalopram
Placebo
20 No 8 T8 140
71
68.6
74.6
41.6 ±12.6
42.6 ±11.6
No 3
3
0
0
Yes
(Katona et al. 1999)(178)
Reboxetine 4-6 No 8 T8 109 77.8 73.8± 6.4 No 6 - Yes
(Katona et al. 2012)(179)
Duloxetine
Placebo
60 No 8 T8 151
145
66.2
62.1
70.9 ± 5.5
70.3 ± 4.4
No -
-
16
3
Yes
(Keegan et al. 1991)(180)
Fluoxetine 53.3± 15.3 No 6 T6 19 66.7 39.5 ±13.6 No 6 5 Yes
(Keller et al. 2007)(181)
Fluoxetine
Venlafaxine
49.8±14.9
208.0±84.0
Yes 10+26+52 T10 266
781
61
65
40.0± 11.6
39.6± 12.2
No 20
22
17
16
Yes
(Khajavi et al. 2012)(182)
Citalopram + Placebo
40 No 6 T6 20 68 36.6 ± 6.8 No - 5 No
(Khan et al. 2007)(183)
Duloxetine
Escitalopram
60
13
Yes 8 T8 133
137
63.9
59.1
43.0± 13.4
41.8± 12.7
No 20
9
8
12
Yes
(Kiev et al. 1997)(184)
Fluvoxamine
Paroxetine
102 ± 44 No 7 T7 30
30
53
53
42.7
39.9
No 9
6
12
9
Yes
(Kim et al. 2011)(185)
Mirtazapine
Paroxetine
30
20
Yes 8 T8 30
30
76.7
66.7
42.4± 9.5
43.9± 9.5
No -
-
8
3
Yes
(Klysner et al. 2002)(186)
Citalopram 10-40 Yes 8+16+48 T8 230 - - No 4 - Yes
(Kranzler et al. 2006)(187)
Sertraline
Placebo
50-200 No 10 T10 159
159
34.0
62.1
41.7± 9.4
43.5± 8.5
Alcohol dependence
22
15
-
-
Yes
(Kyle et al. 1998)(188)
Citalopram 20-40 No 8 T8 179 73.4 73 No - 14 Yes
(Lanctot et al. 2010)(189)
Citalopram 20 No 6 T6 90 40 39.9± 18.0 No - 10 No
(Lapierre et al. 1997)(190)
Fluoxetine 35 ± 8 No 6 T6 62 64.5 40.2± 10.7 No 11 10 Yes
(Learned et al. (study 1) 2012)
(191)
Venlafaxine XR
Placebo
150-225 No 10 T10 133
126
39
37
43.0± 11.2
41.9± 11.8
No 11
7
7
3
Yes
(Learned et al. (study 2) 2012)
(191)
Paroxetine
Placebo
20-30 No 10 T10 166
156
33
39
44.4± 10.9
41.8± 10.9
No 7
8
-
-
Yes
(Lee et al. 2005)(192)
Fluoxetine
Milnacipran
40
100
Yes 6 T6 31
39
74.2
69.2
51 ± 12
49 ± 15
No 2
0
-
-
Yes
(Lee et al. 2007)(193)
Duloxetine
Paroxetine
60
20
Yes 8 T8 237
239
65.5
73.8
39.0± 13.9
38.0± 15.2
No -
-
27
27
Yes
(Lemoine et al. 2007)(44)
Agomelatine
Venlafaxine
25-50
75-150
No 6 T6 166
168
75.2
67.1
40.7± 10.7
39.6± 10.3
No 1
4
7
8
Yes
(Lenox-Smith et al. 2008)
(194)
Citalopram
Venlafaxine
51
191
Yes 12 T12 205
199
64.1
69
43±11.2
42±10.8
No 15
9
-
-
No
(Lepola et al. Citalopram 28.4 Yes 8 T8 160 69.4 44±11 No 7 5 Yes
2003)(195) Escitalopram
Placebo 14.0
155
154
74.8
72.1
43±11
43±12 10
3
8
2
(Lieberman et al. 2008)(196)
Venlafaxine
Venlafaxine
Desvenlafaxine
Placebo
75-150
150-225
200-400
No 8 T8 127
117
231
245
72
70
68
65
46±12
42±12
43±12
42±12
GAD,DAP, social anxiety
disorder
-
-
-
-
12
22
31
16
Yes
(Liebowitz et al. 2007)(197)
Desvenlafaxine
Placebo
179.0-195.3 No 8 T8 121
117
56
65
41.9±12.5
39.3±12.9
No 21
13
14
7
Yes
(Liebowitz et al. 2008)(198)
Desvenlafaxine
Desvenlafaxine
Placebo
50
100
No 8 T8 151
148
152
62
53
63
43±15
43±13
42±14
No 14
15
5
-
-
-
Yes
(Lin et al. 2011)(199)
Sertraline + Placebo
50 Yes 10 T10 20 80 35.2 ±10.0 No 0 1 No
(Lineberry et al. 1990)(200)
Bupropion
Placebo
286.8 No 6 T6 110
109
-
-
41.9
40.8
No 25
8
-
-
Yes
(Lopez-Ibor et al. 2004)(201)
Milnacipran 100 Yes 6 T6 51 74.5 18-70 No 11 - Yes
(Lydiard et al. 1997)(202)
Sertraline
Placebo
138.6 No 8 T8 132
129
64.4
66.7
41.2
40.2
No 8
3
14
7
Yes
(Mao et al. 2008)(203)
Escitalopram
Fluoxetine
10
20
Yes 8 T8 118
113
47.5
61.9
37.1±14.1
40.7±13.9
No -
-
8
7
Yes
(Marchesi et al. 1998)(204)
Fluoxetine 20 Yes 10 T10 67 73.1 43.6± 11.9 No - 1 Yes
(Masco et al. 1994)(205)
Bupropion + Placebo
333 No 6 T6 58 50 46.3 No 6 2 Yes
(Mathur et al. 2002)(206)
Mirtazapine 22. 9±10.5 No 6 T6 18 - - No 1 - No
(Mathur et al. 2005)(207)
Citalopram 36.0 ± 16.7 No 6 T6 20 55 - No 0 0 No
(Mehtonen et al. 2000)(208)
Sertraline
Venlafaxine
50-100
75-150
Yes 8 T8 72
75
66.7
65.3
41.0± 10.7
44.1± 11.4
No 8
9
8
5
Yes
(Mizukami et al. 2006)(209)
Milnacipran 15-75 No 12 T12 11 81.8 75.2 ± 9.4 Alzheimer's disease
- 2 No
(Moffaert et al. 1995)(210)
Mirtazapine 24-72 Yes 6 T6 100 69 46.1 ±10.8 No - 13 Yes
(Mohamed et al. 2006)(211)
Escitalopram 16.6±4.4 Yes 12 T12 20 30 73.0±4.8 Gad - 1 Yes
(Möller et al. 1993)(212)
Paroxetine 30 Yes 6 T6 112 - - No 54 22 No
(Möller et al. 2000)(213)
Sertraline 55 Yes 6 T6 115 63.4 47.7± 13.2 No - 0 No
(Montgomery et al. 2004)
(214)
Escitalopram
Venlafaxine
12.1
95.2
Yes 8 T8 146
142
73.3
71.1
49 ±15
47±14
No 11
14
9
4
Yes
(Moore et al. 2005)(215)
Citalopram
Escitalopram
40
20
Yes 8 T8 142
138
61.9
71.7
46.2± 11.1
44.1± 10.9
No 1
2
3
0
Yes
(Munizza et al. 2006)(216)
Sertraline 50-100 Yes 6 T6 60 70 46.9± 10.6 No 3 3 Yes
(Nemeroff et al. 2007)(217)
Fluoxetine
Venlafaxine
Placebo
41±17
142±64
Yes 6 T6 104
102
102
69
65
56
37.9±11.5
40.1± 11.1
40.4± 11.7
No 15
22
14
-
-
-
Yes
(Newhouse et al. 2000)(218)
Fluoxetine
Sertraline
20-40
50-100
Yes 12 T12 118
116
51.3
63.2
67± 5.9
68± 5.3
No 17
16
-
-
Yes
(Nierenberg et al. 2007)(219)
Duloxetine
Escitalopram
Placebo
60
10
Yes 8 T8 273
274
137
63.4
67.9
63.5
41.1±11.6
43.3±13.0
42.5±12.3
No 22
21
9
16
18
5
Yes
(Nonacs et al. 2005)(220)
Bupropion 262.5 Yes 8 T8 8 100 31.5 GAD,DAP, anxiety disorder
NOS
2 - Yes
(Oliè et al. 2007)(221)
Escitalopram 12.1± 4.2 Yes 12 T12 790 70.5 44.5 ±12.5 Anxiety disorders
30 12 Yes
(Onder et al. 2003)(222)
Fluoxetine
Fluoxetine
20
40
No 12 T12 34
32
50
53.1
35.6± 7.7
34.5± 8.6
No 7
17
-
-
No
(Otsubo et al. 2005)(223)
Fluvoxamine 95.1 Yes 8 T8 36 50 45.3± 13.9 No - 12 No
(Ou et al. 2010)(224)
Citalopram
Escitalopram
27.6
13.9
No 6 T6 117
115
53.8
58.3
36.4± 12.3
36.7± 12.5
No 4
3
-
-
No
(Pae et al. 2004)(225)
Paroxetine 20-40 Yes 8 T8 52 59.6 43.0± 15.0 No 2 10 Yes
(Pae et al. 2008)(226)
Escitalopram 18.3 No 8 T8 17 70.6 43.9± 11.2 No 1 3 Yes
(Park et al. 2012)(227)
Escitalopram 9.0 ± 3.8 Yes 12 T12 79 100 49.1±7.6 No - 5 Yes
(Patris et al. 1996)(228)
Citalopram
Fluoxetine
20
20
Yes 8 T8 173
184
79.2
75.5
44
43
No 8
10
-
-
Yes
(Perahia et al. 2006)(229)
Duloxetine
Duloxetine
Paroxetine
Placebo
80
120
20
Yes 8+26 T8 93
103
97
99
66.7
74.8
71.1
65.7
46.5 ±12.7
44.0± 10.8
45.8± 10.6
44.7± 10.1
No 3
6
6
0
1
3
5
0
Yes
(Perahia et al. 2008)(230)
Duloxetine
Venlafaxine
79.4 ± 22.7
189.7±37.5
No 12 T12 330
337
69.7
153.2
44.3±12.8
41.6±12.3
No 38
39
36
32
Yes
(Perlis et al. 2003)(231)
Fluoxetine
Fluoxetine
48.9± 17.6
45.0± 13.0
Yes 12 T12 9
27
67
48
37.2±12.4
35.8±11.2
No 7
6
-
-
No
(Perry et al. 1989)(232)
Fluoxetine 20-60 No 12 T12 21 57.1 42 ± 10 No - 4 No
(Rabkin et al. 1994)(233)
Sertraline 50-200 No 24 T8 28 3.6 41.0±6.6 Dysthymia 4 - Yes
(Rapaport et al. 1996)(234)
Fluoxetine
Fluvoxamine
34.2±18.8
101.9±34.2
Yes 7 T7 47
50
66
62
38.6
40.0
Dysthymia, anxiety disorder
NOS
13
18
-
-
Yes
(Rapaport et al. 2003)(235)
Paroxetine CR
Paroxetine IR
Placebo
30.4
25.7
No 12 T12 104
106
109
48.1
56.6
63.3
70.4±5.9
70.1±6.6
69.4±5.4
No 10
15
9
-
-
-
Yes
(Rapaport et al. 2009)(236)
Paroxetine CR
Paroxetine CR
Placebo
12.5
25
Yes 10 T10 164
73
179
60
60
63
67±6.11
67±6.56
68±6.73
Anxiety disorders, disthymia
14
9
11
9
5
5
Yes
(Raskin et al. 2003)(237)
Duloxetine 80-120 Yes 52 T8 1279 72.6 44.4 ±13.2 No 318 354 Yes
(Raskin et al. 2007)(238)
Duloxetine
Placebo
60 No 8 T8 207
104
60.4
57.7
72.6±5.7
73.3±5.7
Mild dementia 8
5
11
1
Yes
(Rickels et al. 1985)(239)
Fluoxetine
Fluoxetine
20-80 q.d.
20-80 b.i.d.
No 6+48 T6 94
94
60
60
37
37
No 14
9
-
-
No
(Rickels et al. 1992)(240)
Paroxetine
Placebo
31.5 ± 1.25 Yes 6 T6 55
56
69.2
59.1
43.4
46.0
No 9
5
13
4
No
(Roose et al. 2004)(241)
Citalopram
Placebo
10-40 No 8 T8 84
90
53.6
62.2
79.8 ± 4.0
79.3 ± 4.7
No 3
5
5
4
Yes
(Rosso et al. 2012)(242)
Bupropion
Duloxetine
300
120
Yes 6 T6 21
25
71.4
64
46.6
47.6
No 1
0
-
-
No
(Rudolph et al. 1998)(243)
Venlafaxine
Venlafaxine
Venlafaxine
Placebo
75
225
375
No 6 T6 89
89
88
92
40
43
33
32
43.6
43.1
43.8
41.5
No 20
18
12
9
15
16
23
4
Yes
(Rudolph et al. 1999)(244)
Fluoxetine
Venlafaxine XR
Placebo
47
175
Yes 8 T8 103
100
98
73
69
64
40
40
40
No -
-
-
12
8
6
Yes
(Russell et al. 2001)(245)
Sertraline 141.0±59.4 No 6 T6 155 65.1 41.6± 10.6 SUD, anxiety disorders,
personality disorders
43 - Yes
(Sacchetti et al. 2002)(246)
Paroxetine 20-50 Yes 12 T12 64 64.1 48.7 No 3 3 No
(Samuelian et al. 1998)(247)
Venlafaxine 105 Yes 6 T6 52 73.1 47 ± 12 No - 3 Yes
(Schatzberg et al. 2002)(248)
Mirtazapine
Paroxetine
25.7 ± 6.7
26.5 ± 5.5
No 8+16 T8 126
120
50
53.3
71.7 ± 5.7
72.0 ± 5.1
No 15
14
39
37
Yes
(Schatzberg et al. 2006)(249)
Fluoxetine
Venlafaxine
Placebo
20-60
37.5-225
Yes 8 T8 100
104
96
56
45
46
71±5
71±5
71±5
No 11
10
4
8
13
4
Yes
(Schneider et al. 2003)(250)
Sertraline
Placebo
50-100 Yes 8 T8 371
376
54
58
70.0 ± 6.8
69.6 ± 6.5
Alcohol dependence, disthymia, GAD, PD
35
23
38
16
Yes
(Schöne et al. 1993)(251)
Fluoxetine
Paroxetine
20-60
20-40
Yes 6 T6 52
54
90.4
83.3
73.7
74.3
No 7
5
-
-
Yes
(Schweizer et al. 1994)(252)
Venlafaxine
Placebo
83-179 No 6 T6 73
78
71
67
41±13
42±12
No 15
10
19
11
Yes
(Sepanjnia et al. 2012)(253)
Citalopram + Placebo
30 Yes 6 T6 20 75 32.7±5.4 Specific phobia 4 - No
(Septien-Velez et al. 2007)
(254)
Desvenlafaxine
Desvenlafaxine
200
400
No 8 T8 123
125
45.4±11.9
43.4±10.9
No -
-
12
7
Yes
Placebo 125 46.7±12.1 - 2
(Sheehan et al. 2009)(255)
Fluoxetine
Venlafaxine
Placebo
58±13.7
235±74.8
Yes 6 T6 99
94
95
69
48
64
37.8 ±11.1
41.7±12.8
39.9±13.0
No 18
18
8
-
-
-
Yes
(Sheikh et al. 2004)(256)
Sertraline
Placebo
50-100 No 8 T8 226
232
54.4
53.8
70.1±6.7
70.0±6.6
No 23
17
23
10
Yes
(Shelton et al. 2006)(257)
Sertraline
Venlafaxine
50-100
75-225
Yes 8 T8 82
76
46.3
63.2
41.2 ±12.0
37.2±11.6
Personality disorders, other axis I but MD as
primary diagnosis
19
14
-
-
Yes
(Shrivastava et al. 1992)(258)
Paroxetine
Placebo
22.0-45.5 Yes 6 T6 40
40
27.5
35
38
34.6
No -
-
10
6
Yes
(Silverstone et al. 1999)(259)
Fluoxetine
Venlafaxine XR
Placebo
39.9
140.8
Yes 12 T12 121
128
119
59.7
63.9
57.6
43.2± 10.9
41.1± 12.0
41.6± 10.8
Anxiety disorders
30
41
12
17
17
7
Yes
(Sir et al. 2005)(260)
Sertraline
Venlafaxine XR
105.4±29.5
161.4±44.4
No 8 T8 79
84
72.2
66.7
37.3± 13.5
36.8± 12.4
No 28
23
17
22
Yes
(Smith et al. 1990)(261)
Mirtazapine
Placebo
18 No 6 T6 50
50
58
58
43
43
No -
-
32
8
No
(Smith et al. 1992)(262)
Paroxetine
Placebo
33.8 No 6 T6 39
38
38.5
47.4
44.9
44.6
No 8
2
7
3
Yes
(Soares et al. 2010)
Desvenlafaxine 177.2±40.6 No 8+26 T8 296 100 56± 6 No 39 48 Yes
(
263)_ENREF_232
Escitalopram 18.1±3.9 299 100 56± 6 33 42
(Sögaard et al. 1999)(264)
Sertraline 83.1 Yes 12 T12 99 79.8 42.1± 11.1 No 19 4 Yes
(Sonawalla et al. 1999)(265)
Fluvoxamine 143±45 No 12 T12 30 53.3 39.4 ±11.3 No 11 - Yes
(Sonawalla et al. 2002)(266)
Fluoxetine 20 No 8 T8 123 49 38.9 ±10.8 Anxiety disorders
21 - No
(Stahl et al. 2010)(267)
Agomelatine
Placebo
50 No 8 T8 167
165
63.9
64.5
43.8 ±12.0
43.0±13.1
No 11
10
30
7
Yes
(Steen et al. 1997)(268)
Milnacipran 200 No 6+20 T6 30 30 48.1 ±15.2 No 10 - No
(Steffens et al. 2001)(269)
Bupropion IR or SR
250-258 No 12 T12 15 - - No 1 - Yes
(Stewart et al. 2008)(270)
Duloxetine 74±44 No 8 T8 20 55 35 ± 12 Dysthymia. PD 3 3 Yes
(Stuppaeck et al. 1994)(271)
Paroxetine 33.3 No 6 T6 78 70.5 47.5± 11.6 No 8 3 Yes
(Taner et al. 2006)(272)
Fluoxetine
Reboxetine
20-40
8-10
No 8 T8 21
22
78.4
78.4
36.8± 11.0
36.8± 11.0
No 1
4
-
-
No
(Taragano et al. 1999)(273)
Sertraline 50-100 No 8 T8 469 73 57.4± 13.9 No 9 5 Yes
(Thase et al. 1997)(274)
Venlafaxine 75-225 Yes 8 T8 95 63.2 40±11 No 33 26 Yes
Placebo 102 59.8 42±12 15 11
(Thase et al. 1997)(275)
Fluoxetine 37.2 No 6 T6 106 72 42.9±12.1 No 22 18 Yes
(Thase et al. 2002)(276)
Citalopram 23.9 No 6 T6 61 52.5 43.0±11.9 No 1 5 No
(Thase et al. 2006)(277)
Bupropion
Venlafaxine
299.6±77.1
149.8±41.3
No 12 T12 168
174
56
64
37.1± 12.3
37.4± 11.6
No -
-
2
12
Yes
(Tollefson et al. 1994)(278)
Fluoxetine 20-40 No 8 T8 62 71 40.1± 11.7 No 19 - Yes
(Tollefson et al. 1995)(279)
Fluoxetine
Placebo
20 Yes 6 T6 335
336
53.7
55.4
67.7±5.7
67.7±5.7
No 61
42
-
-
Yes
(Torta et al. 2011)(280)
Duloxetine 83.5 Yes 12 T12 27 40.7 63.6 ±10.9 No 1 - Yes
(Tourian et al. 2009)(281)
Duloxetine
Desvenlafaxine
Desvenlafaxine
Placebo
60
50
100
No 8 T8 157
148
150
160
66
69
66
58
39±12
41±13)
39±12
39±13
No 29
16
21
5
23
9
17
4
Yes
(Tzanakaki et al. 2000)(282)
Fluoxetine
Venlafaxine
20-60
75-225
Yes 6 T6 54
55
83.3
74.5
49±10
47±11
No 1
7
-
-
Yes
(Tzeng et al. 2009)(283)
Mirtazapine 33.2 No 7 T7 58 55.2 47.7 ±16.6 SUD - 4 No
(Urbina et al. 1999)(284)
Fluoxetine 20 Yes 6 T6 20 95 34.4± 1.8 No 5 - No
(Vanderkooy et al. 2002)(285)
Bupropion 143.3±25.8 No 8 T8 15 73.3 41.1± 8.8 No 5 3 No
Sertraline
Venlafaxine
Paroxetine
105.4±217.5
81.4±58.4
18.7±6.1
37
62
55
81.1
61.3
38.2
39.5± 11.4
40.8± 11.2
38.1± 11.3
5
16
7
12
17
16
(Ventura et al. 2007)(286)
Escitalopram
Sertraline
10
113.6
Yes 8 T8 104
107
54.8
59.8
40.6± 13.7
38.1± 11.5
No 14
18
12
6
Yes
(Versiani et al. 1999)(287)
Fluoxetine 20 No 8 T8 77 - - No 3 11 No
(Versiani et al. 2000)(288)
Reboxetine
Placebo
10 Yes 6 T6 28
28
46.4
50
41.7
40.0
No 7
0
-
-
Yes
(Versiani et al. 2005)(289)
Fluoxetine
Mirtazapine
20-40
10-60
Yes 8 T8 147
145
69
74
47
43
No 13
7
14
20
Yes
(Volonteri et al. 2010)(290)
Duloxetine 74.0± 24.6 No 12 T12 45 36 59.6± 12.8 Personality disorders, SUD
4 4 No
(Volpe et al. 2008)(291)
Dluoxetine 60 Yes 8 T8 30 93.3 41 ± 8 No 9 8 Yes
(Waintraub et al. 2002)(292)
Paroxetine + Placebo
20 Yes 12 T12 139 66.7 41 No 0 2 No
(Wakeno et al. 2008)(293)
Milnacipran
Paroxetine
60.0± 16.9
27.8± 7.5
Yes 6 T6 30
27
43.3
51.9
49.3± 12.6
48.3± 15.0
No -
-
3
1
Yes
(Weihs et al. 2000)(294)
Bupropion
Paroxetine
197± 53
22 ± 7
No 6 T6 48
52
54
60
69.2
71.0
No 6
8
3
14
Yes
(Weihs et al. 2002)(295)
Bupropion 277± 30.9 Yes 8+44 T8 816 68 39.4 No 131 - Yes
(Weisler et al. Bupropion 279 No 6 T6 62 53.2 40.2 No 9 5 Yes
1994)(296)
(Wheatley et al. 1998)(297)
Fluoxetine
Mirtazapine
23.8± 3.8 Yes 6 T6 66
66
59
55
47.5 ±14.8
47.2 ±15.3
No -
-
9
12
Yes
(Wijkstra et al. 2010)(298)
Venlafaxine 372.3± 14.2 Yes 7 T7 39 43.6 49.5± 12.0 No 1 1 Yes
(Wohlreich et al. 2004)(299)
Duloxetine 80-120 Yes 52 T8 101 71.3 71.9± 5.4 No 15 22 Yes
(Wohlreich et al. 2007)(300)
Duloxetine 91.9 Yes 6+104 T6 128 61.8 42.6±13.3 No 9 6 Yes
(Wohlreich et al. 2007)(301)
Duloxetine 60 Yes 7 T7 3431 75.4 48.0 ±12.9 No 210 74 Yes
(Yargic et al. 2004)(302)
Paroxetine 27.6 ± 9.5 No 8 T8 54 81.5 35.9± 13.7 No 6 - No
(Yevtushenko et al. 2007)
(303)
Citalopram
Citalopram
Escitalopram
10
20
10
No 6 T6 106
108
108
57.5
56.5
61.1
34.8 ±0.6
35.1±0.6
35.2±0.6
No -
-
-
2
0
0
No
(Yonkers et al. 2008)(304)
Paroxetine
Placebo
21.1 ±10.7 No 8 T8 35
35
100
100
26.1 ± 6.5
25.9 ± 6.5
No -
-
5
5
Yes
(Zajecka et al. 2010)(305)
Agomelatine
Agomelatine
Placebo
25
50
No 8 T8 162
163
169
66.7
66.7
66.7
43.8± 12.2
43.8± 12.2
43.8± 12.2
No 8
9
18
9
14
10
Yes
*=Note that the table does not report the antidepressants not included in the study.
GAD= generalized anxiety disorder; PD= panic disorder; NOS=not otherwise specified, SUD=substance use disorder
References
65. Abbasi SH, Hosseini F, Modabbernia A, et al., Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major
depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 2012;141:308-314.
66. Abolfazli R, Hosseini M, Ghanizadeh A, et al., Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus
modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety 2011;28:297-302.
67. Aguglia E, Casacchia M, Cassano GB, et al., Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin
Psychopharmacol 1993;8:197-202.
68. Akhondzadeh S, Faraji H, Sadeghi M, et al., Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major
depression. J Clin Pharm Ther 2003;28:379-384.
69. Akhondzadeh S, Jafari S, Raisi F, et al., Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo
controlled trial. Depress Anxiety 2009;26:607-611.
70. Akkaya C, Sivrioglu EY, Akgoz S, et al., Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major
depression with anxiety features: an open label study. Hum Psychopharmacol 2006;21:337-345.
71. Alvarez E, Perez V, Dragheim M, et al., A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major
depressive disorder. Int J Neuropsychopharmacol 2012;15:589-600.
72. Amini H, Aghayan S, Jalili SA, et al., Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind,
randomized trial. J Clin Pharm Ther 2005;30:133-138.
73. Andreoli V, Caillard V, Deo RS, et al., Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of
depression. J Clin Psychopharmacol 2002;22:393-399.
74. Ansseau M, Gabriels A, Loyens J, et al., Controlled Comparison of Paroxetine and Fluvoxamine in Major Depression. Hum Psychopharmacol 1994;9:329-
336.
75. Appelhof BC, Brouwer JP, van Dyck R, et al., Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Endocrinol
Metab 2004;89:6271-6276.
76. Baldwin D, Moreno RA and Briley M, Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Hum
Psychopharmacol 2008;23:527-532.
77. Baldwin DS, Loft H and Dragheim M, A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu
AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22:482-491.
78. Benkert O, Szegedi A and Kohnen R, Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61:656-663.
79. Benkert O, Szegedi A, Philipp M, et al., Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized
multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 2006;26:75-78.
80. Benkert O, Grunder G, Wetzel H, et al., A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients
with major depression and melancholia. J Psychiatr Res 1996;30:441-451.
81. Berk M, du Plessis AD, Birkett M, et al., An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in
patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group. Int Clin Psychopharmacol 1997;12:137-140.
82. Berzewski H, Van Moffaert M and Gagiano CA, Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients
suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;7 Suppl 1:S37-47; discussion S71-73.
83. Bielski RJ, Ventura D and Chang CC, A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive
disorder. J Clin Psychiatry 2004;65:1190-1196.
84. Blier P, Ward HE, Tremblay P, et al., Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind
randomized study. Am J Psychiatry 2010;167:281-288.
85. Blier P, Gobbi G, Turcotte JE, et al., Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from
treatment initiation. Eur Neuropsychopharmacol 2009;19:457-465.
86. Bondareff W, Alpert M, Friedhoff AJ, et al., Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J
Psychiatry 2000;157:729-736.
87. Bose A, Li D and Gandhi C, Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 2008;16:14-20.
88. Boyer P, Tassin JP, Falissart B, et al., Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major
depression. J Clin Pharm Ther 2000;25:363-371.
89. Boyer P, Montgomery S, Lepola U, et al., Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder
in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-253.
90. Brannan SK, Mallinckrodt CH, Brown EB, et al., Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major
depressive disorder. J Psychiatr Res 2005;39:43-53.
91. Brecht S, Courtecuisse C, Debieuvre C, et al., Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major
depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007;68:1707-1716.
92. Bremner JD, A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-525.
93. Brown ES, Vigil L, Khan DA, et al., A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of
concept study. Biol Psychiatry 2005;58:865-870.
94. Brown WA and Harrison W, Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry
1995;56:30-34.
95. Burke WJ, Gergel I and Bose A, Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-336.
96. Byerley WF, Reimherr FW, Wood DR, et al., Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J
Clin Psychopharmacol 1988;8:112-115.
97. Calabrese JR, Londborg PD, Shelton MD, et al., Citalopram treatment of fluoxetine-intolerant depressed patients. J Clin Psychiatry 2003;64:562-567.
98. Chouinard G, Saxena B, Belanger MC, et al., A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J
Affect Disord 1999;54:39-48.
99. Claghorn JL, Kiev A, Rickels K, et al., Paroxetine versus placebo: a double-blind comparison in depressed patients. J Clin Psychiatry 1992;53:434-438.
100. Claghorn JL and Lesem MD, A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-171.
101. Claghorn JL, Earl CQ, Walczak DD, et al., Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled
comparison with imipramine in outpatients. J Clin Psychopharmacol 1996;16:113-120.
102. Clayton AH, Croft HA, Horrigan JP, et al., Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant
efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67:736-746.
103. Clerc GE, Ruimy P and Verdeau-Palles J, A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and
melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9:139-143.
104. Clerc G, Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
Int Clin Psychopharmacol 2001;16:145-151.
105. Cohn JB and Wilcox C, A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985;46:26-31.
106. Cohn JB and Wilcox CS, Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry 1992;53 Suppl:52-56.
107. Coleman CC, Cunningham LA, Foster VJ, et al., Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of
bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11:205-215.
108. Coleman CC, King BR, Bolden-Watson C, et al., A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and
fluoxetine. Clin Ther 2001;23:1040-1058.
109. Cooper-Kazaz R, Apter JT, Cohen R, et al., Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind,
placebo-controlled trial. Arch Gen Psychiatry 2007;64:679-688.
110. Corrigan MH, Denahan AQ, Wright CE, et al., Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety
2000;11:58-65.
111. Costa e Silva J, Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998;59:352-
357.
112. de Vasconcelos Cunha UG, Lopes Rocha F, Avila de Melo R, et al., A placebo-controlled double-blind randomized study of venlafaxine in the treatment
of depression in dementia. Dement Geriatr Cogn Disord 2007;24:36-41.
113. Cunningham LA, Borison RL, Carman JS, et al., A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol
1994;14:99-106.
114. Cunningham LA, Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression.
Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 1997;9:157-164.
115. Currier MB, Molina G and Kato M, A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients.
Psychosomatics 2003;44:120-125.
116. Currier MB, Molina G and Kato M, Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study.
Psychosomatics 2004;45:210-216.
117. Dam J, Ryde L, Svejso J, et al., Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of
major depression. Pharmacopsychiatry 1998;31:48-54.
118. de Montigny C, Silverstone PH, Debonnel G, et al., Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin
Psychopharmacol 1999;19:401-406.
119. Debus JR, Rush AJ, Himmel C, et al., Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry 1988;49:422-
426.
120. DeMartinis NA, Yeung PP, Entsuah R, et al., A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the
treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-688.
121. Demir B, Soykan A, Devrimci-Ozguven H, et al., An open label clinical trial of reboxetine in patients with major depressive disorder. Eur
Neuropsychopharmacol 2002;12 Supplement:3:S221-S221.
122. Detke MJ, Lu Y, Goldstein DJ, et al., Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res
2002;36:383-390.
123. Detke MJ, Wiltse CG, Mallinckrodt CH, et al., Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-
controlled trial. Eur Neuropsychopharmacol 2004;14:457-470.
124. Diaz-Martinez A, Benassinni O, Ontiveros A, et al., A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin
Ther 1998;20:467-476.
125. Dierick M, Ravizza L, Realini R, et al., A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog
Neuropsychopharmacol Biol Psychiatry 1996;20:57-71.
126. Doogan DP and Langdon CJ, A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general
practice. Int Clin Psychopharmacol 1994;9:95-100.
127. Dube S, Dellva MA, Jones M, et al., A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major
depression. J Psychiatr Res 2010;44:356-363.
128. Dunbar GC, Cohn JB, Fabre LF, et al., A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 1991;159:394-398.
129. Dunner DL, Cohn JB, Walshe T, 3rd, et al., Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major
depression. J Clin Psychiatry 1992;53 Suppl:57-60.
130. Dunner DL, Wohlreich MM, Mallinckrodt CH, et al., Clinical Consequences of Initial Duloxetine Dosing Strategies: Comparison of 30 and 60 mg QD
Starting Doses. Curr Ther Res 2005;66:523-540.
131. Eker SS, Akkaya C, Akgoz S, et al., [Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder]. Turk Psikiyatri
Derg 2005;16:153-163.
132. Elliott AJ and Roy-Byrne PP, Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 2000;20:265-267.
133. Fabre L, Birkhimer LJ, Zaborny BA, et al., Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Int Clin
Psychopharmacol 1996;11:119-127.
134. Fabre LF, A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry 1992;53 Suppl:40-43.
135. Fava M, Amsterdam JD, Deltito JA, et al., A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin
Psychiatry 1998;10:145-150.
136. Fava M, Dunner DL, Greist JH, et al., Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label
trial. J Clin Psychiatry 2001;62:413-420.
137. Fava M, Alpert J, Nierenberg AA, et al., A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin
Psychopharmacol 2005;25:441-447.
138. Fava M, McCall WV, Krystal A, et al., Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Biol Psychiatry 2006;59:1052-1060.
139. Fava M, Asnis GM, Shrivastava RK, et al., Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major
depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled
trial. J Clin Psychiatry 2011;72:914-928.
140. Feiger A, Kiev A, Shrivastava RK, et al., Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on
sexual function and satisfaction. J Clin Psychiatry 1996;57 Suppl 2:53-62.
141. Feighner JP, Gardner EA, Johnston JA, et al., Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry
1991;52:329-335.
142. Feighner JP and Overo K, Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry
1999;60:824-830.
143. Feighner JP, Boyer WF, Merideth CH, et al., A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int
Clin Psychopharmacol 1989;4:127-134.
144. Feighner JP, Boyer WF, Meredith CH, et al., A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int
Clin Psychopharmacol 1989;4:239-244.
145. Ferreri M, Lavergne F, Berlin I, et al., Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to
fluoxetine alone. Acta Psychiatr Scand 2001;103:66-72.
146. Finkel SI, Richter EM, Clary CM, et al., Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am J Geriatr
Psychiatry 1999;7:221-227.
147. Flores J and Iglesias G, Efficacy of mirtazapine in daily clinical practice in Venezuela: response and remission rates. J Affect Disord 2004;78 Supplement
1:S120-S120.
148. Forlenza OV, Almeida OP, Stoppe A, Jr., et al., Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the
treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Int Psychogeriatr 2001;13:75-84.
149. Fornaro M, Martino M, Battaglia F, et al., Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60
mg/day: a preliminary observation. Neuropsychiatr Dis Treat 2011;7:51-56.
150. Fortner MR, Brown K, Varia IM, et al., Effect of Bupropion SR on the Quality of Life of Elderly Depressed Patients With Comorbid Medical Disorders.
Prim Care Companion J Clin Psychiatry 1999;1:174-179.
151. Garlow SJ, Dunlop BW, Ninan PT, et al., The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the
treatment of major depressive disorder. J Psychiatr Res 2012;46:1406-1413.
152. Gaynor PJ, Gopal M, Zheng W, et al., A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated
painful physical symptoms. Curr Med Res Opin 2011;27:1849-1858.
153. Gaynor PJ, Gopal M, Zheng W, et al., Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical
symptoms: a replication study. Curr Med Res Opin 2011;27:1859-1867.
154. Geretsegger C, Stuppaeck CH, Mair M, et al., Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients.
Psychopharmacology (Berl) 1995;119:277-281.
155. Golden RN, Nemeroff CB, McSorley P, et al., Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of
depression. J Clin Psychiatry 2002;63:577-584.
156. Goldstein DJ, Mallinckrodt C, Lu Y, et al., Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry
2002;63:225-231.
157. Goldstein DJ, Lu Y, Detke MJ, et al., Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin
Psychopharmacol 2004;24:389-399.
158. Guelfi JD, Ansseau M, Corruble E, et al., A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int
Clin Psychopharmacol 1998;13:121-128.
159. Guelfi JD, Ansseau M, Timmerman L, et al., Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin
Psychopharmacol 2001;21:425-431.
160. Hale A, Corral RM, Mencacci C, et al., Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized,
double-blind study. Int Clin Psychopharmacol 2010;25:305-314.
161. Halikas J, Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995;10:S125-S133.
162. Hewett K, Gee MD, Krishen A, et al., Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and
venlafaxine XR. J Psychopharmacol 2010;24:1209-1216.
163. Hewett K, Chrzanowski W, Jokinen R, et al., Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major
depressive disorder. J Psychopharmacol 2010;24:521-529.
164. Higuchi T, Hong JP, Jung HY, et al., Paroxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-
blind, placebo-controlled study in Japan and Korea. Psychiatry Clin Neurosci 2011;65:655-663.
165. Hong CJ, Hu WH, Chen CC, et al., A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with
mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003;64:921-926.
166. Hoyberg OJ, Maragakis B, Mullin J, et al., A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta
Psychiatr Scand 1996;93:184-90.
167. Hsu JW, Su TP, Huang CY, et al., Faster onset of antidepressant effects of citalopram compared with sertraline in drug-naive first-episode major
depressive disorder in a Chinese population: a 6-week double-blind, randomized comparative study. J Clin Psychopharmacol 2011;31:577-581.
168. Hudson JI, Perahia DG, Gilaberte I, et al., Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatry 2007;7:43.
169. Isaac MT, Isaac MB, Gallo F, et al., Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency. Hum Psychopharmacol
2003;18:595-601.
170. Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al., Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine,
separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008;42:192-198.
171. Jefferson JW, Rush AJ, Nelson JC, et al., Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced
energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006;67:865-873.
172. Kamijima K, Burt T, Cohen G, et al., A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. Int Clin
Psychopharmacol 2006;21:1-9.
173. Kanemoto K, Matsubara M, Yamashita K, et al., Controlled comparison of two different doses of milnacipran in major depressive outpatients. Int Clin
Psychopharmacol 2004;19:343-346.
174. Kang EH, Lee IS, Chung SK, et al., Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a
randomized, open-labeled trial. Psychiatry Res 2009;169:118-123.
175. Kaplan EM, Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake
inhibitors: an open-label, uncontrolled study. Clin Ther 2002;24:1194-1200.
176. Kasper S, de Swart H and Friis Andersen H, Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005;13:884-891.
177. Kasper S, Ebert B, Larsen K, et al., Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major
depressive disorder. Int J Neuropsychopharmacol 2012;15:715-725.
178. Katona C, Bercoff E, Chiu E, et al., Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind
randomised trial. J Affect Disord 1999;55:203-213.
179. Katona C, Hansen T and Olsen CK, A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and
safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27:215-223.
180. Keegan D, Bowen RC, Blackshaw S, et al., A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int Clin Psychopharmacol
1991;6:117-124.
181. Keller MB, Trivedi MH, Thase ME, et al., The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study:
outcomes from the acute and continuation phases. Biol Psychiatry 2007;62:1371-1379.
182. Khajavi D, Farokhnia M, Modabbernia A, et al., Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized,
double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:1428-1433.
183. Khan A, Bose A, Alexopoulos GS, et al., Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Clin Drug Investig 2007;27:481-492.
184. Kiev A and Feiger A, A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry
1997;58:146-152.
185. Kim JE, Yoon SJ, Kim J, et al., Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label
randomised paroxetine-controlled trial. Int J Clin Pract 2011;65:323-329.
186. Klysner R, Bent-Hansen J, Hansen HL, et al., Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled
study of maintenance therapy. Br J Psychiatry 2002;181:29-35.
187. Kranzler HR, Mueller T, Cornelius J, et al., Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol
2006;26:13-20.
188. Kyle CJ, Petersen HE and Overo KF, Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in
general practice. Depress Anxiety 1998;8:147-153.
189. Lanctot KL, Rapoport MJ, Chan F, et al., Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury.
Brain Inj 2010;24:959-969.
190. Lapierre YD, Joffe R, McKenna K, et al., Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. J Psychiatry Neurosci
1997;22:118-126.
191. Learned S, Graff O, Roychowdhury S, et al., Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with
major depressive disorder: two randomized, placebo- and active-controlled clinical trials. J Psychopharmacol 2012;26:653-662.
192. Lee MS, Ham BJ, Kee BS, et al., Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Curr Med Res
Opin 2005;21:1369-1375.
193. Lee P, Shu L, Xu X, et al., Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized,
paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry Clin Neurosci 2007;61:295-307.
194. Lenox-Smith AJ and Jiang Q, Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake
inhibitor. Int Clin Psychopharmacol 2008;23:113-119.
195. Lepola UM, Loft H and Reines EH, Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary
care. Int Clin Psychopharmacol 2003;18:211-217.
196. Lieberman DZ, Montgomery SA, Tourian KA, et al., A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int
Clin Psychopharmacol 2008;23:188-197.
197. Liebowitz MR, Yeung PP and Entsuah R, A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with
major depressive disorder. J Clin Psychiatry 2007;68:1663-1672.
198. Liebowitz MR, Manley AL, Padmanabhan SK, et al., Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with
major depressive disorder. Curr Med Res Opin 2008;24:1877-1890.
199. Lin CH, Lin SH and Jang FL, Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized,
double-blind, controlled study. J Clin Psychopharmacol 2011;31:563-568.
200. Lineberry CG, Johnston JA, Raymond RN, et al., A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin
Psychiatry 1990;51:194-199.
201. Lopez-Ibor JJ and Conesa A, A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. Curr Med Res Opin
2004;20:855-860.
202. Lydiard RB, Stahl SM, Hertzman M, et al., A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the
treatment of major depression. J Clin Psychiatry 1997;58:484-491.
203. Mao PX, Tang YL, Jiang F, et al., Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a
Chinese population. Depress Anxiety 2008;25:46-54.
204. Marchesi C, Ceccherininelli A, Rossi A, et al., Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with
amitriptyline. Pharmacopsychiatry 1998;31:216-221.
205. Masco HL, Kiev A, Holloman LC, et al., Safety and efficacy of bupropion and nortriptyline in outpatients with depression. Curr Ther Res 1994;55:851-
863.
206. Mathur A, Chowdhary A and Jain M, A comparative study of the efficacy and safety of mirtazapine versus amitriptyline in the treatment of major
depression. Indian J Psychiatry 2002;44:260-265.
207. Mathur A, Sharma DK, Choudhary A, et al., Efficacy and safety of citalopram versus amitriptyline in the treatment of major depression. Indian J
Psychiatry 2005;47:89-93.
208. Mehtonen OP, Sogaard J, Roponen P, et al., Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive
disorder. Venlafaxine 631 Study Group. J Clin Psychiatry 2000;61:95-100.
209. Mizukami K, Tanaka Y and Asada T, Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease. Prog Neuropsychopharmacol
Biol Psychiatry 2006;30:1342-1346.
210. van Moffaert M, de Wilde J, Vereecken A, et al., Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients
with major depression. Int Clin Psychopharmacol 1995;10:3-9.
211. Mohamed S, Osatuke K, Aslam M, et al., Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose,
pilot trial. Am J Geriatr Pharmacother 2006;4:201-209.
212. Moller HJ, Berzewski H, Eckmann F, et al., Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry
1993;26:75-78.
213. Moller HJ, Glaser K, Leverkus F, et al., Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major
depression. Pharmacopsychiatry 2000;33:206-212.
214. Montgomery SA, Huusom AK and Bothmer J, A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major
depressive disorder. Neuropsychobiology 2004;50:57-64.
215. Moore N, Verdoux H and Fantino B, Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in
outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-137.
216. Munizza C, Olivieri L, Di Loreto G, et al., A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment
of major depressive disorder. Curr Med Res Opin 2006;22:1703-1713.
217. Nemeroff CB and Thase ME, A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J
Psychiatr Res 2007;41:351-359.
218. Newhouse PA, Krishnan KR, Doraiswamy PM, et al., A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin
Psychiatry 2000;61:559-568.
219. Nierenberg AA, Greist JH, Mallinckrodt CH, et al., Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive
disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007;23:401-416.
220. Nonacs RM, Soares CN, Viguera AC, et al., Bupropion SR for the treatment of postpartum depression: a pilot study. Int J Neuropsychopharmacol
2005;8:445-449.
221. Olie JP, Tonnoir B, Menard F, et al., A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of
anxiety. Depress Anxiety 2007;24:318-324.
222. Onder E and Tural U, Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. J Affect Disord
2003;76:223-227.
223. Otsubo T, Akimoto Y, Yamada H, et al., A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese
patients with major depression. Pharmacopsychiatry 2005;38:30-35.
224. Ou JJ, Xun GL, Wu RR, et al., Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized,
double-blind, flexible-dose study. Psychopharmacology (Berl) 2011;213:639-646.
225. Pae CU, Kim YJ, Won WY, et al., Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. Hum
Psychopharmacol 2004;19:25-29.
226. Pae CU, Masand PS, Peindl K, et al., An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder
with atypical features. Prim Care Companion J Clin Psychiatry 2008;10:205-210.
227. Park HY, Lee BJ, Kim JH, et al., Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-
week, open-label prospective trial. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:318-323.
228. Patris M, Bouchard JM, Bougerol T, et al., Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar
major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-136.
229. Perahia DG, Wang F, Mallinckrodt CH, et al., Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur
Psychiatry 2006;21:367-378.
230. Perahia DG, Pritchett YL, Kajdasz DK, et al., A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with
major depressive disorder. J Psychiatr Res 2008;42:22-34.
231. Perlis RH, Mischoulon D, Smoller JW, et al., Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry
2003;54:879-883.
232. Perry PJ, Garvey MJ, Kelly MW, et al., A comparative trial of fluoxetine versus trazodone in outpatients with major depression. J Clin Psychiatry
1989;50:290-294.
233. Rabkin JG, Wagner G and Rabkin R, Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J
Clin Psychiatry 1994;55:433-439.
234. Rapaport M, Coccaro E, Sheline Y, et al., A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol
1996;16:373-378.
235. Rapaport MH, Schneider LS, Dunner DL, et al., Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry
2003;64:1065-1074.
236. Rapaport MH, Lydiard RB, Pitts CD, et al., Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-
controlled trial. J Clin Psychiatry 2009;70:46-57.
237. Raskin J, Goldstein DJ, Mallinckrodt CH, et al., Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003;64:1237-1244.
238. Raskin J, Wiltse CG, Siegal A, et al., Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-
week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-909.
239. Rickels K, Smith WT, Glaudin V, et al., Comparison of two dosage regimens of fluoxetine in major depression. J Clin Psychiatry 1985;46:38-41.
240. Rickels K, Amsterdam J, Clary C, et al., The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. J Clin
Psychiatry 1992;53 Suppl:30-32.
241. Roose SP, Sackeim HA, Krishnan KR, et al., Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-
controlled trial. Am J Psychiatry 2004;161:2050-2059.
242. Rosso G, Rigardetto S, Bogetto F, et al., A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major
depression. J Affect Disord 2012;136:172-176.
243. Rudolph RL, Fabre LF, Feighner JP, et al., A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major
depression. J Clin Psychiatry 1998;59:116-122.
244. Rudolph RL and Feiger AD, A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the
treatment of depression. J Affect Disord 1999;56:171-181.
245. Russell JM, Koran LM, Rush J, et al., Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress
Anxiety 2001;13:18-27.
246. Sacchetti E, Cassano GB, Penati G, et al., Paroxetine versus amitriptyline in patients with recurrent major depression: A double-blind trial. Int J Psych
Clin Pract 2002;6:23-29.
247. Samuelian JC and Hackett D, A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major
depression. J Psychopharmacol 1998;12:273-278.
248. Schatzberg AF, Kremer C, Rodrigues HE, et al., Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J
Geriatr Psychiatry 2002;10:541-550.
249. Schatzberg A and Roose S, A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J
Geriatr Psychiatry 2006;14:361-370.
250. Schneider LS, Nelson JC, Clary CM, et al., An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly
outpatients with major depression. Am J Psychiatry 2003;160:1277-1285.
251. Schone W and Ludwig M, A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin
Psychopharmacol 1993;13:34S-39S.
252. Schweizer E, Feighner J, Mandos LA, et al., Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin
Psychiatry 1994;55:104-108.
253. Sepanjnia K, Modabbernia A, Ashrafi M, et al., Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-
blind placebo-controlled trial. Neuropsychopharmacology 2012;37:2093-2100.
254. Septien-Velez L, Pitrosky B, Padmanabhan SK, et al., A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment
of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-347.
255. Sheehan DV, Nemeroff CB, Thase ME, et al., Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major
depression with melancholic features. Int Clin Psychopharmacol 2009;24:61-86.
256. Sheikh JI, Cassidy EL, Doraiswamy PM, et al., Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical
illness. J Am Geriatr Soc 2004;52:86-92.
257. Shelton RC, Haman KL, Rapaport MH, et al., A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive
disorder. J Clin Psychiatry 2006;67:1674-1681.
258. Shrivastava RK, Shrivastava SH, Overweg N, et al., A double-blind comparison of paroxetine, imipramine, and placebo in major depression. J Clin
Psychiatry 1992;53 Suppl:48-51.
259. Silverstone PH and Ravindran A, Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety.
Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999;60:22-28.
260. Sir A, D'Souza RF, Uguz S, et al., Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin
Psychiatry 2005;66:1312-1320.
261. Smith WT, Glaudin V, Panagides J, et al., Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull
1990;26:191-196.
262. Smith WT and Glaudin V, A placebo-controlled trial of paroxetine in the treatment of major depression. J Clin Psychiatry 1992;53 Suppl:36-39.
263. Soares CN, Thase ME, Clayton A, et al., Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder.
Menopause 2010;17:700-711.
264. Sogaard J, Lane R, Latimer P, et al., A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J
Psychopharmacol 1999;13:406-414.
265. Sonawalla SB, Spillmann MK, Kolsky AR, et al., Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin
Psychiatry 1999;60:580-583.
266. Sonawalla SB, Farabaugh A, Johnson MW, et al., Fluoxetine treatment of depressed patients with comorbid anxiety disorders. J Psychopharmacol
2002;16:215-219.
267. Stahl SM, Fava M, Trivedi MH, et al., Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-
controlled trial. J Clin Psychiatry 2010;71:616-626.
268. Steen A and Den Boer JA, A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Int Clin
Psychopharmacol 1997;12:269-281.
269. Steffens DC, Doraiswamy PM and McQuoid DR, Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr
Psychiatry 2001;16:862-865.
270. Stewart JW, Deliyannides DA and McGrath PJ, Is duloxetine effective treatment for depression with atypical features? Int Clin Psychopharmacol
2008;23:333-336.
271. Stuppaeck CH, Geretsegger C, Whitworth AB, et al., A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin
Psychopharmacol 1994;14:241-246.
272. Taner E, Demir EY and Cosar B, Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind,
randomized clinical trial. Adv Ther 2006;23:974-987.
273. Taragano F, Lyketsos CG, Paz J, et al., An open-label trial of sertraline for the treatment of major depression in primary care. Ann Clin Psychiatry
1999;11:67-71.
274. Thase ME, Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study
Group. J Clin Psychiatry 1997;58:393-398.
275. Thase ME, Blomgren SL, Birkett MA, et al., Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J
Clin Psychiatry 1997;58:16-21.
276. Thase ME, Ferguson JM, Lydiard RB, et al., Citalopram treatment of paroxetine-intolerant depressed patients. Depress Anxiety 2002;16:128-133.
277. Thase ME, Clayton AH, Haight BR, et al., A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant
efficacy, and tolerability. J Clin Psychopharmacol 2006;26:482-488.
278. Tollefson GD, Greist JH, Jefferson JW, et al., Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative
trial of fluoxetine versus imipramine. J Clin Psychopharmacol 1994;14:385-391.
279. Tollefson GD, Bosomworth JC, Heiligenstein JH, et al., A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major
depression. The Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995;7:89-104.
280. Torta R, Leombruni P, Borio R, et al., Duloxetine for the treatment of mood disorder in cancer patients: a 12-week case-control clinical trial. Hum
Psychopharmacol 2011;26:291-299.
281. Tourian KA, Padmanabhan SK, Groark J, et al., Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III,
multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009;31 Pt
1:1405-1423.
282. Tzanakaki M, Guazzelli M, Nimatoudis I, et al., Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major
depression and melancholia. Int Clin Psychopharmacol 2000;15:29-34.
283. Tzeng DS, Chien CC, Lung FW, et al., MAOA gene polymorphisms and response to mirtazapine in major depression. Hum Psychopharmacol
2009;24:293-300.
284. Urbina M, Pineda S, Pinango L, et al., [3H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before
and after treatment with fluoxetine. Int J Immunopharmacol 1999;21:631-646.
285. Vanderkooy JD, Kennedy SH and Bagby RM, Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion,
moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002;47:174-180.
286. Ventura D, Armstrong EP, Skrepnek GH, et al., Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
Curr Med Res Opin 2007;23:245-250.
287. Versiani M, Ontiveros A, Mazzotti G, et al., Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious
depression): a double-blind comparison. Int Clin Psychopharmacol 1999;14:321-327.
288. Versiani M, Amin M and Chouinard G, Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J
Clin Psychopharmacol 2000;20:28-34.
289. Versiani M, Moreno R, Ramakers-van Moorsel CJ, et al., Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS
Drugs 2005;19:137-146.
290. Volonteri LS, Colasanti A, Cerveri G, et al., Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week
study with plasma levels. J Psychopharmacol 2010;24:1193-1199.
291. Volpe FM, An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry 2008;69:1449-
1454.
292. Waintraub L, Septien L and Azoulay P, Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus
paroxetine. CNS Drugs 2002;16:65-75.
293. Wakeno M, Kato M, Okugawa G, et al., The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. J Clin
Psychopharmacol 2008;28:518-524.
294. Weihs KL, Settle EC, Jr., Batey SR, et al., Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry
2000;61:196-202.
295. Weihs KL, Houser TL, Batey SR, et al., Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol
Psychiatry 2002;51:753-761.
296. Weisler RH, Johnston JA, Lineberry CG, et al., Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol
1994;14:170-179.
297. Wheatley DP, van Moffaert M, Timmerman L, et al., Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to
severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry 1998;59:306-312.
298. Wijkstra J, Burger H, van den Broek WW, et al., Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine,
venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand 2010;121:190-200.
299. Wohlreich MM, Mallinckrodt CH, Watkin JG, et al., Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older:
an open-label study. BMC Geriatr 2004;4:11.
300. Wohlreich MM, Mallinckrodt CH, Prakash A, et al., Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with
dose escalation. Depress Anxiety 2007;24:41-52.
301. Wohlreich MM, Wiltse CG, Desaiah D, et al., Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of
depression in an open-label, multicenter study. Prim Care Companion J Clin Psychiatry 2007;9:271-279.
302. Yargic LI, Corapcioglu A, Kocabasoglu N, et al., A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine
with and without quetiapine therapy in depression associated with anxiety. Int J Psych Clin Pract 2004;8:205-211.
303. Yevtushenko VY, Belous AI, Yevtushenko YG, et al., Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week,
multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007;29:2319-2332.
304. Yonkers KA, Lin H, Howell HB, et al., Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized
controlled trial with paroxetine. J Clin Psychiatry 2008;69:659-665.
305. Zajecka J, Schatzberg A, Stahl S, et al., Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized,
double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010;30:135-144.
